Related Experiment Videos
Overview of clinical experience with ciprofloxacin
European Journal of Clinical Microbiology
|April 1, 1986
Summary
Ciprofloxacin, a novel 4-quinolone antibiotic, offers broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. Oral ciprofloxacin demonstrates clinical efficacy in various infections with a favorable safety profile.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Ciprofloxacin represents a new generation of 4-quinolone antibiotics.
- It exhibits enhanced potency and a broader spectrum of activity compared to earlier agents.
- Its pharmacokinetic profile allows for therapeutic concentrations in serum, tissues, and urine following oral administration.
Purpose of the Study:
- To review the efficacy and safety of oral ciprofloxacin.
- To highlight its activity against a wide range of pathogens, including resistant strains.
- To assess its potential in treating infections traditionally managed with parenteral therapy.
Main Methods:
- This is an overview based on existing clinical data and studies.
- Clinical effectiveness was evaluated across various infection types.
- Adverse event profiles were assessed.
Main Results:
- Ciprofloxacin is active against Gram-positive cocci and opportunistic pathogens like Pseudomonas aeruginosa.
- Clinically effective in treating urinary, respiratory, gastro-intestinal, gonorrhoea, surgical, and skin/soft tissue infections.
- Demonstrated particular efficacy in Pseudomonas aeruginosa infections, including cystic fibrosis.
Conclusions:
- Oral ciprofloxacin is effective and well-tolerated for a wide array of infections.
- It presents a significant advancement for oral antibiotic therapy, offering an alternative to parenteral treatments.
- Adverse reactions are generally mild and transient, supporting its therapeutic potential.